A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon
Recommended Citation
Crowell C, Zhu Z, Li Y, Varela ML, Ostrom Q, Cimino PJ, Patel SH, Baker SJ, Bettegowda C, Noushmehr H, Kleinman CL, Canty L, Cruzeiro GAV, Nellan A, Becher O, Davidson TB, Hambardzumyan D, Green A, Thorne R, Wilson K, Theeler B, Gregory J, Mathen P, Biassou N, McThenia S, Erker C, Galvin R, Soldatos A, Lowenstein PR, Castro MG, and Jackson S. A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon. NPJ Precis Oncol 2025;9(1):283.
Document Type
Article
Publication Date
8-14-2025
Publication Title
NPJ Precis Oncol
Abstract
Diffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood. Combining previous published studies with findings from the 2024 NIH G34-mutant symposium aid in summarizing translational and clinical updates on disease development, cellular repair processes, and the immune microenvironment. This collective work is meant to outline opportunities for treatment and prolonged survival.
PubMed ID
40813437
Volume
9
Issue
1
First Page
283
Last Page
283
